ABSTRACT The inhibitory activity of an ω-alkoxy analogue of the HDAC inhibitor, Vorinostat (SAHA), against the 11 isoforms of HDAC is described and evaluated with regard to structural biology information retrieved through computational methods. Preliminary absorption and metabolism studies were performed, which positioned this compound as a potential candidate for further preclinical studies and delineated measures for improving its pharmacokinetic profile.
I
n spite of the significant progress made in HDAC research, [1] [2] [3] [4] the quest for isoform-selective inhibitors continues to present a major challenge. [5] [6] [7] To date, detailed biostructural information is available only regarding a few among the known 11 metallo-enzymes. 1, [8] [9] [10] [11] Consequently, the design of isoform-and class-selective inhibitors is somewhat arbitrary and derivative. 1, 7, [12] [13] [14] In addition, complete data regarding the factual HDAC profile for most of the early discovered agents are not available, since the development of effective isozyme-based assays is relatively recent. [5] [6] [7] [15] [16] [17] [18] As a consequence of the complex, pleiotropic nature of cancer, promiscuous HDAC inhibitors such as Vorinostat (1) (SAHA, suberoylanilide hydroxamic acid) 19 ( Figure 1 ) seem superior and as safe in the clinic as compared to the few class-specific agents available. [5] [6] [7] 15 Ligand-based approaches are a first-choice solution to delineate the structural requirements for HDAC selectivity, especially with the emergence of ω-aryl alkanoyl hydroxamates such as Vorinostat as clinical candidates. 1, 7, [12] [13] [14] In this regard, simple and readily accessible surrogates are worthy of study, provided that they bear pharmacophoric determinants as close as possible to a maximum common substructural consensus required to target the whole HDAC panel. The judicious inclusion of specific appendages capable of interacting with specific residues in the cap region of HDACs can provide valuable structural, functional, and stereochemical insight into the design of new inhibitors.
In a previous study, we determined the optimal alkyl chain length for activity against a single isoform, HDAC2. 20 Designed for understanding the role of the chirality in simple ω-alkoxy analogues of Vorinostat, compound (R/S)-2 emerged as a promising lead for its preliminary cytotoxic activity against leukemia, colon, and lung tumor cell lines. Here, we describe the details for the improved and shortened synthesis of 2, together with the biostructural insights through molecular modeling and a preliminary study of its in vitro activity against an extended panel of HDACs.
Although relatively simple in conception, the previous nine-step synthesis of racemic 2 20 was shortened and adapted to produce gram-scale material for pharmacological studies (Supporting Information) (Scheme 1). The required 8-carbon chain of (R/S)-2 was assembled by a cross metathesis reaction 21 between an excess of methyl acrylate and the olefin 3, readily available from (R/S)-glycidol, 22 in the presence of Grubbs' second generation catalyst in CH 2 Cl 2 at 40°C. Catalytic reduction to the methyl ester 4, followed by Sc(OTf) 3 -assisted O-alkylation with PMB trichloroacetimidate, 23 led to 5. This was deprotected with TBAF, and the product was submitted to a Swern oxidation to obtain aldehyde 6 in 94% yield for two steps. Jones oxidation of 6 led to the carboxylic acid intermediate, which was immediately coupled as a crude with aniline in the presence of Goodman's reagent (DEBPT), 24 leading to anilide 7 in 75% yield. Finally, conversion to hydroxamic acid (R/S)-2 was easily achieved by treating methyl ester 7 with hydroxylamine and NaOH in MeOH. Enantiopure 2 could be obtained starting from (R)-or (S)-3 or by Mitsunobu inversion of configuration of the individual alcohols. 20 Using this protocol, the synthesis of (R/S)-2 was achieved in seven steps from 3 in 37% overall yield.
In preliminary testing against HeLa immunopurified HDAC2 assay, 20 (R/S)-2 exhibited comparable if not improved nanomolar potency over Vorinostat. Surprisingly, no significant difference in inhibitory activity was found between (R/S)-2 and its individual enantiomers against this HDAC isoform. 25 A subsequent antiproliferative evaluation against three different human cancer cell lines (NB4, H460, and HCT-116) substantiated the potential of 2 as a promising candidate for further profiling. The potency of racemic and enantiopure 2 to inhibit 11 isolated human HDAC isozymes in the presence of a fluorogenic peptide bound to the RHKK(Ac) fragment of p53 (residues 379-382) as the substrate is shown in Table 1 . 18 Vorinostat, 19 trichostatin A (TSA), 26 and NVP-LAQ824 27 were used as reference compounds.
From this investigation, we confirmed the role of 2 as a promiscuous inhibitor, displaying an activity comparable to Vorinostat against all HDACs. No significant difference was found between the racemic 2 and its individual enantiomers, which proved to be equipotent against all of the zincdependent HDACs. To gain more insight into this equivalence, a docking analysis of the individual enantiomers of 2 was performed based on the crystal structures of HDAC8 8 and HDAC7, 9 which were chosen as representatives of class I and II HDACs, respectively ( Figure 2) . 28 In binding these isoforms, a T-shape arrangement was observed for both enantiomers of ligand 2, which projected its aromatic motifs out from the active site channel toward lipophilic pockets located in opposite directions on the enzyme surface. The Phe208 and Phe152 residues in the rim of HDAC8 were found to engage in π-π interactions with either the anilide or the p-methoxybenzyl moieties of each enantiomer. The relative distances between each Phe residue and the aromatic moieties of both enantiomers, together with the corresponding number of interactions, are shown in Table 2 . 29 The sum of π-π interactions produced by the (S)-and (R)-enantiomers of 2 with both Phe residues was found to be almost the same in HDCA8. Overall, 13 interactions were detected in the case of (S)-2, and 11 were detected in the case of (R)-2, which may account for the slight difference shown by the enantiomers in binding this isoform [IC 50(R)/(S) = 3.3]. The binding was further stabilized by interactions between the amide bonds of the (R)-and (S)-isomers with a conserved water molecule as well as with a conserved Asp residue 8 (Asp101 in HDAC8). In addition, a H-bond between the methoxy group of the (S)-isomer and the Lys33 in HDAC8 contributed to stabilization of the complex. This Lys residue is peculiar to HDAC8 8 and may also play a part in the small difference in activity between the enantiomers.
Upon binding to HDAC7, analogous interactions were observed in the rim of this isozyme, involving Phe738 (Phe208 in HDAC8), Phe679 (Phe152 in HDAC8), and the aromatic groups of both enantiomers of 2. In this case, three and four π-π interactions stabilizing the complex of (S)-and (R)-2, respectively, via their anilide and PMB rings, were recorded as compared to HDAC8 ( Table 2) . A conserved water molecule stabilized the isomers through interactions with the amide and the ether bonds of (S)-2 and (R)-2, respectively. An interaction was found between the Asp626 and the amide bond of (R)-2, which might explain its marginally higher activity over the (S)-enantiomer [IC 50(S)/(R) = 3.4]. In addition, further π-π interactions were observed between the Phe737 and the PMB ring of (R)-2 and pubs.acs.org/acsmedchemlett the anilide motif of (S)-2, equally reinforcing the binding of both enantiomers.
Despite the different Phe binding interaction sites observed for the two isomers of 2 against these HDACs, the levels of their inhibitory activity were not appreciably changed. Overall, their binding mode suggested that the lipophilic interactions had a major role in stabilizing their individual complexes. 30 In part, our hypothesis is also confirmed by a detailed structural comparison between HDAC1 and HDAC8. 31 Considering the high level of conservation of Phe residues among the HDAC isoforms, [8] [9] [10] [11] these interactions might explain the lack of discrimination between the individual enantiomers.
It has been recently argued that the enzymatic activity associated with class IIa HDACs ectopically expressed in mammalian cells might be the result of a residual contamination by class I HDACs present in class IIa immunocomplexes. 16 In view of this possibility, we deemed it necessary to extend our assay to include this method of HDAC profiling with (R/S)-2. The in vitro test was performed in the presence of the class IIa-specific fluorogenic substrate acetyl-Lys-(trifluoroacetyl)-AMC, using Vorinostat and TSA as the reference compounds (Table 3 ; see also the Supporting Information). Given the low sensitivity of this substrate, a remarkable decrease in the activity for all of the tested compounds was observed, which was in the micromolar range. For this reason, the two enantiomers of 2 were not tested. Although compound (R/S)-2 was found to be as active as Vorinostat against HDAC7 and HDAC9, and slightly less active against HDAC5, it was totally inactive toward HDAC4.
Thus, a dramatic difference was observed between the activities of (R/S)-2 and Vorinostat in the class IIa-specific assay against HDAC4, as compared to the results shown in Table 1 in the class I-II-IV profiling assay. As suggested by the Gallinari group, 16 this might be due to the presence of a residual deacetylase activity from contaminant class I HDACs in traditional profiling assays. The generality of this observation must be validated by a careful scrutiny of the appropriate substrates and the purity of recombinant isoenzymes enabling accurate HDAC profiling. 3, [5] [6] [7] [15] [16] [17] Preliminary assays were performed on (R/S)-2 to assess its absorption and metabolism. Human colorectal carcinomaderived cells (Caco-2 cell line) were used as an established in vitro model for the prediction of (R/S)-2 absorption across the human intestine. 32 A transport study was performed to obtain apparent permeability coefficients (P app ) in the apical to basolateral direction, and the result was compared to Figure 2 . Left: best docking solutions of (S)-2 (yellow) and (R)-2 (green) on HDAC8 crystal structure.
28 Right: best docking solutions of (S)-2 (yellow) and (R)-2 (green) on HDAC7 crystal structure. Vorinostat and to the reference compounds cimetidine, vinblastine, and caffeine (Supporting Information). According to this model, a high intestinal permeability can be predicted for P app coefficients higher than 50. In this assay, a good level of oral absorption was predicted for (R/S)-2, which showed a P app value higher than Vorinostat (P app = 219.2 vs P app = 77.6 nm/s) and comparable to caffeine (P app = 312.4 nm/s).
The metabolism study was performed upon incubation of (R/S)-2 with human cryopreserved hepatocytes (HC2 and H655) and by subsequent quantification of the remaining parent compound from the incubated supernatant by UPLC. 33 The metabolic stability was defined as the percentage of parent compound lost over time in the active test system. Vorinostat was used as a reference compound, together with 7-ethoxycoumarin and 7-hydroxycoumarin as the positive controls of hepatocyte competence for phase I and II metabolism, respectively (0.42% left after 90 min at 1 μM concentration and 2.08% left under the same conditions). 33 Although a lower stability was observed for (R/S)-2 as compared to Vorinostat (23% left after 90 min at 1 μM concentration vs 61% left under the same conditions for Vorinostat), measures for improving its pharmacokinetic profile can be taken based on the chemical modification at specific sites. 34 In conclusion, we have studied the structural and stereochemical effects of an optimized ω-alkoxy analogue of Vorinostat as a probe to assess its in vitro activity profile against 11 isoforms of HDAC. Although a higher permeability was noted for compound 2 in the Caco-2 assay as compared to Vorinostat, a faster rate of metabolism was observed. It is possible that O-demethylation or benzylic carbon oxidation is taking place, which could be avoided with appropriate functional group modifications. Results pertaining to these and other variations will be disclosed in due course. Funding Sources: We thank NSERC of Canada for financial assistance. A postdoctoral grant from Wenner-Gren Foundation, Sweden, is kindly acknowledged by A.L.
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